Status:
UNKNOWN
Combined Neoadjuvant Systemic and PIPAC Therapy (NASPIT) for Patients With Colorectal Peritoneal Metastasis Eligible for CRS and HIPEC: A Prospective Phase II Trial
Lead Sponsor:
Prof. Aviram Nissan
Conditions:
Metastatic Colorectal Cancer
Peritoneal Carcinomatosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel drug-delivery system developed to deliver, effectively and safely, small doses of cytotoxic agents into peritoneal tumor deposits. I...
Detailed Description
This is an open label, single arm, single center, phase II trial to study the added efficacy benefit of PIPAC administered in the neoadjuvant setting in combination with systemic therapy for patients ...
Eligibility Criteria
Inclusion
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study and must be willing to return for follow-up
- 18 years of age or older.
- Biopsy (histopathology or cytology) diagnosis of colorectal cancer as defined by the WHO or by cross-sectional imaging reviewed by a board-certified radiologist.
- Good performance status (ECOG \< 2), Karnofski \>60.
- Patients with low or acceptable surgical risk (American Society of Anesthesiology (ASA) score of 3 or less.
- Patient is a candidate for CRS and HIPEC as discussed and recommended by the institutional disease management team (DMT, Tumor Board)
- Patient receiving systemic chemotherapy for up to a maximum of 6 months from peritoneal diagnosis management with stable or responsive disease are eligible for the trial.
- Absolute neutrophil count (ANC) exceeds 1200/mm3, white blood cell count exceeds 4000/mm3 and platelet count is greater than 100,000/mm3
- An international normalized ratio (INR) ≤ 1.5 (patients who are therapeutically anticoagulated for non-related medical conditions such as atrial fibrillation and whose anti-thrombotic treatment can be withheld for operation will be eligible
- Adequate hepatic function must be met as evidenced by total serum bilirubin ≤ 1.5 mg/dl (patients with total bilirubin \> 1.5 mg/dL eligible only with Gilbert's syndrome); alkaline phosphatase \< 2.5 times the upper limit of normal; and, AST less than 1.5 times upper limit of normal \[alkaline phosphatase and AST cannot both exceed the upper limit of normal
- Serum renal functional parameters, BUN and creatinine are within normal limits
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening or with negative pregnancy test at screening.
- Life expectancy of at least six months
Exclusion
- Patients with unresectable (not eligible for CRS/HIPEC) tumors as decided by a multidisciplinary disease management team
- Patients that already received multiple cycles of systemic chemotherapy of more than 6 months and or show progression of disease on systemic therapy.
- Patients with extraperitoneal disease.
- Pregnancy or lactation
- Patients with low performance status (ECOG \> 2 or Karnofski \< 60%)
- Any one or more of the following hematological abnormalities
- Hgb \< 8gm/dl unable to be corrected with transfusion
- Absolute Neutrophil Count \< 1200/mm3
- White blood cell count \< 4000/mm3
- Platelet count \< 100,000/mm3
- INR \> 1.5 (except in patients who are therapeutically AST anticoagulated for non-related medical conditions such as atrial fibrillation and whose anti-thrombotic treatment cannot be withheld for operation will be eligible)
- History of hepatic cirrhosis or present hepatic dysfunction
- Alkaline phosphatase ≥ 2.5 times the upper limit of normal
- ≥ 1.5 times upper limit of normal
- Serum bilirubin \> 1.5 mg/dl (except for patients with Gilbert's syndrome who must have direct bilirubin ≤ 1.0 mg/dl)
- Alkaline phosphatase and AST both exceed the upper limit of normal
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04475159
Start Date
August 1 2020
End Date
August 1 2023
Last Update
July 17 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.